2 results
6-K
EX-99
RLFTF
Relief Therapeutics Holding AG
9 Oct 24
Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
4:30pm
in the coming weeks.
Culture-based studies have shown that up to 93% of wounds in EB patients are colonized by Staphylococcus species. “Overgrowth
6-K
EX-99
RLFTF
Relief Therapeutics Holding AG
10 May 24
Relief Therapeutics Announces New Executive Leadership Team strengthening capabilities to guide the Company through pipeline development initiatives
4:30pm
activities, including talent management, culture building, and leadership development. Ms. Keegan joined Relief in 2022 on a consulting basis and played
- Prev
- 1
- Next